Abstract Novel rifamycins such as ABI-0043, ABI-0369, and ABI-0699 had comparable in vivo bactericidal activity with ceftriaxone against a penicillin-G-resistant, mefA-positive Streptococcus pneumoniae in a murine pneumonia model. ABI-0043 demonstrated a dosedependent response with a high correlation to bacterial kill (ϩ0.1 to Ϫ3.7 log 10 CFU).
For new compounds, like ABI-0043, that have potent antipneumococcal activity in in vitro studies, the assessment of their bactericidal activity in a murine pneumococcal pneumonia model can provide an estimate of future clinical success. This study was reported in part at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 16 to 19 December 2005.
The purpose of this study was to evaluate the antibacterial activity of ActivBiotics' compounds ABI-0043, ABI-0369 and ABI-0699 in comparison to rifampin and/or ceftriaxone administered intraperitoneally once to thrice daily over time ranging from 6 to 24 hours in the S. pneumoniae murine pneumonia model. Drug substance of New Chemical Entities (NCE) (ABI-0043, ABI-0369, and ABI-0699) was supplied by ActivBiotics, Inc. (Fig. 1) ; ceftriaxone was obtained from Roche Pharmaceuticals (Nutley, NJ); rifampin was obtained from Bedford Laboratories (Bedford, OH).
Three clinical isolates of S. pneumoniae were utilized for in vitro susceptibility testing: one penicillin-G-susceptible (SPN 21), one mefA (SPN 100; penicillin-resistant), and one ermB (SPN 95; penicillin-susceptible) isolate. The phenotypic and genotypic profile for these isolates has been previously confirmed [8ϳ10] . All isolates were maintained in skim milk medium (BD Biosciences, Sparks, Md.) at Ϫ80°C and subcultured twice on trypticase soy agar with 5% sheep blood (BD Biosciences) before use in in vitro and in vivo experiments [8] . MICs of NCEs and rifampin were determined against S. pneumoniae strains SPN 21, SPN 95, and SPN 100 in triplicate using standard CLSI (previously NCCLS) methods [11] . The in vitro activity of NCEs was superior to that of rifampin and penicillin G (Table 1 ) and comparable to that of each other, especially for strains SPN 95 and SPN 100. The penicillin-resistant strain SPN 100 was chosen for in vivo studies.
Specific pathogen-free, female ICR (approximately 22 g) mice (Harlan, Inc., Indianapolis, IN) were managed and utilized according to National Research Council recommendations and were provided food and water adlibitum [12] . Mice were rendered neutropenic by IP injection of cyclophosphamide (Cytoxan; Bristol-Myers Squibb, Princeton, N.J.) 150 mg/kg at four days and 100 mg/kg at 1 day prior to inoculation [13, 14] . Pneumonia was induced via oropharyngeal inoculation of a 0.05 ml suspension of SPN 100 prepared from an inoculum adjusted to approximately 10 8 CFU/ml as described previously [8] . By 8 to 16 hours post inoculation, all animals showed signs of infection including rough coat appearance and limited mobility. IP treatment with antibacterial or normal saline (control) began 12ϳ14 hours post inoculation for groups of 6 mice as follows (also see Fig. 2 ): QD doses of ABI-0043 at 0.4, 4.0, 40 and 80 mg/kg, ABI-0369 and ABI-0699 at 80 mg/kg, ceftriaxone at 4.0 mg/kg and 40 mg/kg and rifampin at 10 mg/kg. All mice treated QD were sacrificed at 6 hours post treatment. ABI-0043 was also dosed at 120 and 240 mg/kg/day (q8h, 3 doses of 40 and 80 mg/kg, respectively) and the mice in these groups were sacrificed at 24 hours. The drug vehicle was as follows: 375 g of Etocas 35NF, 4.4 g pluronic acid F68, 50.8 g PEG 400, and 10.8 ml of water. Dimethyl sulfoxide (Ͼ99.9%, Sigma-Aldrich Corp., St. Louis, MO) was added to the powder and mixed with vehicle. A group of 6 control mice was sacrificed just prior to initiation of dosing and at the time of lung harvest (at 6 hours for the single dose groups and at 24 hours for groups receiving 3 doses) for each treatment regimen. Lungs were aseptically removed and individually homogenized in 1.0 ml of normal saline as described previously [8] . Serial dilutions of homogenate were plated on trypticase soy agar with 5.0% sheep blood and subsequently incubated at 35°C for 24 hours in 5.0% CO 2 for CFU determination.
In the untreated control groups, both the 0 and 6 hours CFU levels in lung tissue were consistent between runs, starting at 10 6 to 10 7 CFU with an increase by about 1 log 24 hours post inoculation. The change in bacterial density in the lung tissues was calculated by subtracting the mean log 10 CFU of the control mice sacrificed just prior to dosing from the mean log 10 CFU of the drug treated and control mice at the end of 6 or 24 hours of therapy. Antibiotic-carry over was observed upon culturing the lung homogenates after the 3 doses of ABI-0043 80 mg/kg q8h, and as such, the limit of detection was 2ϫ10 4 CFU for this group. Fig. 2 displays the change in log 10 CFU/ml for control and treatment groups. The IP dosing of ABI-0043 produced a dose-dependent killing effect. The bacterial density decreased proportionally with an increase of total dosage when compared with the bacterial density of the same hour control animals (ϩ0.1 to Ϫ3.7 log 10 CFU). This relationship was confirmed by analysis of data with WinNonlin 5.0 (Pharsight Co., Cary, NC) and SigmaPlot 2001 (SPSS Inc., Chicago, IL) each of which gave a high correlation (R 2 ϭ0.994). Statistical analysis was conducted using SigmaStat 2.03 (SPSS Inc., Chicago, IL) with statistical significance defined at p-value of 0.05 or less. Mann-Whitney Rank Sum test, t-test, and one-way ANOVA was applied where appropriate. The 40 mg/kg dose of ABI-0043 showed comparable activity to that of the 40 mg/kg dose of ceftriaxone (Pϭ0.756). The 10 mg/kg dose of rifampin was also similar in efficacy to ABI-0043 at 4 and 40 mg/kg doses (Pϭ0.147).
The extent of in vivo antibacterial activity of ABI-0369 and ABI-0699 was similar to that of the ABI-0043 when 80 mg/kg dose groups were compared (Pϭ0.596), consistent with both potentially similar PK and the similar MICs determined in this study.
The close correlation between the ABI-0043 daily dosage and change in log 10 CFU in lung tissue suggested that ABI-0043 might have concentration-dependent killing.
In conclusion, these novel rifamycins demonstrated excellent in vitro potency against S. pneumoniae having diverse genotypic and phenotypic profiles. In vivo, the NCEs demonstrated significant bacterial killing, which increased in a dose dependent fashion and was similar to ceftriaxone at equal mg/kg doses. These data support the continued preclinical development of this class of compounds towards the indication of respiratory infection. Fig. 2 In vivo antibacterial activity of rifamycin analogs and comparators against SPN100. * pϽ0.05 between log 10 CFU changes in infected mice treated with regimens and infected mice treated with placebo (normal saline) ABI-0043 240 mg/kg/day and 120 mg/kg/day were given as 80 mg q8h and 40 mg q8h. The rest of compounds were given as once daily dose.
